Skip to main content

Table 2 Tumor response data

From: Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

Best overall response* PR SD PR + SD PD
  N (%)
All patients (n = 21) 5 (24) 8 (38) 13 (62) 8 (38)
MSKCC intermediate risk (n = 15) 4 (19) 7 (33) 11 (52) 4 (19)
MSKCC poor risk (n = 6) 1 (5) 1 (5) 2 (10) 4 (19)
Heng intermediate risk (n = 11) 4 (19) 5 (24) 9 (43) 2 (10)
Heng poor risk (n = 10) 1 (5) 3 (14) 4 (19) 6 (29)
  1. *Restaging scans occurred after five doses of AGS-003 and cycles 2-4 of sunitinib. NOTE: Responses were determined relative to a baseline scan conducted after nephrectomy and completion of one (1) 6-week cycle of sunitinib.
  2. PD = progressive disease; PR = partial response; SD = stable disease.